GTSM:4157

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

TaiGen Biopharmaceuticals Holdings

Executive Summary

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for infectious diseases worldwide. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has TaiGen Biopharmaceuticals Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4157 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 4157's weekly volatility has decreased from 10% to 5% over the past year.


Market Performance


7 Day Return

-4.1%

4157

-0.005%

TW Biotechs

2.5%

TW Market


1 Year Return

-8.6%

4157

22.8%

TW Biotechs

31.6%

TW Market

Return vs Industry: 4157 underperformed the TW Biotechs industry which returned 22.8% over the past year.

Return vs Market: 4157 underperformed the TW Market which returned 31.6% over the past year.


Shareholder returns

4157IndustryMarket
7 Day-4.1%-0.005%2.5%
30 Day-16.9%-7.0%11.8%
90 Day-25.1%-2.4%22.9%
1 Year-8.6%-8.6%23.3%22.8%36.3%31.6%
3 Year-20.4%-20.4%-18.4%-19.9%59.7%41.8%
5 Year-33.9%-33.9%-50.0%-50.4%136.2%94.8%

Long-Term Price Volatility Vs. Market

How volatile is TaiGen Biopharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TaiGen Biopharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?

24.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4157's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4157's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4157 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 4157 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4157's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4157 is overvalued based on its PB Ratio (24.4x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is TaiGen Biopharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

86.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiGen Biopharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has TaiGen Biopharmaceuticals Holdings performed over the past 5 years?

-8.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4157 is currently unprofitable.

Growing Profit Margin: 4157 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4157 is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare 4157's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4157 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 4157 has a negative Return on Equity (-87.11%), as it is currently unprofitable.


Next Steps

Financial Health

How is TaiGen Biopharmaceuticals Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 4157's short term assets (NT$470.8M) exceed its short term liabilities (NT$42.7M).

Long Term Liabilities: 4157's short term assets (NT$470.8M) exceed its long term liabilities (NT$23.3M).


Debt to Equity History and Analysis

Debt Level: 4157 is debt free.

Reducing Debt: 4157 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4157 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 4157 has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 13.3% each year.


Next Steps

Dividend

What is TaiGen Biopharmaceuticals Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4157's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4157's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4157's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4157's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4157's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.5yrs

Average management tenure


CEO

Ming-Chu Hsu

19.75yrs

Tenure

NT$15,000

Compensation

Dr. Ming-Chu Hsu, Ph.D. founded TaiGen Biotechnology Co., Ltd. in 2001. She served as Chief Consultant at TaiGen Biotechnology Co., Ltd. since January 2019 to February 2019. Dr. Hsu served as the Chief Exe...


Leadership Team

NamePositionTenureCompensationOwnership
Ming-Chu Hsu
Founder19.75yrsNT$15.00kno data
Richard Lu
Vice President of Finance4.75yrsno datano data
Peter Tsao
Vice President Corporate Development9.42yrsno datano data
Chi-Hsin King
Senior Vice President of Research15.5yrsno datano data

12.5yrs

Average Tenure

Experienced Management: 4157's management team is seasoned and experienced (12.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ming-Chu Hsu
Founder19.75yrsNT$15.00kno data
Ye-Hong Zhang
Independent Director1.58yrsno datano data
Show-Chung Ho
Director7.75yrsNT$123.00kno data
Po-Young Chu
Independent Director9.08yrsNT$1.04mno data
Kuo-Lung Huang
Chairperson2yrsno datano data
Hong-Jen Chang
Director10.58yrsNT$135.00kno data
Kuo-Hsi Wang
Director11.83yrsNT$135.00kno data
Shen-Fu Yu
Independent Director1.58yrsno datano data
Chiung-Feng Ko
Supervisor8.58yrsNT$135.00kno data
Shih-Jen Hsiao
Supervisor7.75yrsNT$120.00kno data
Yen-Hua Huang
Directorno datano datano data
Weng-Foung Huang
Independent Directorno datano datano data

8.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 4157's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TaiGen Biopharmaceuticals Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TaiGen Biopharmaceuticals Holdings Limited
  • Ticker: 4157
  • Exchange: GTSM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$13.262b
  • Shares outstanding: 716.84m
  • Website: https://www.taigenbiotech.com.tw

Location

  • TaiGen Biopharmaceuticals Holdings Limited
  • No. 138, Xinming Road
  • 7th Floor
  • Taipei City
  • 11470
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4157GTSM (Taipei Exchange)YesCommon StockTWTWDSep 2013

Biography

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for infectious diseases worldwide. Its marketed product is Taigexyn (Nemonoxacin), a novel non-fluorinated ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 08:44
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.